ReviewResearch and reports in urology2025
Patient Reported Outcomes and Treatment-Associated Complications as a Consideration in Selecting Localized Prostate Cancer Management.
Review in Research and reports in urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Population-Level Resources and Costs Associated with Low-Risk Prostate Cancer Patients on Active Surveillance.Cancers · 2026Article
- Article
- Quality of life in older adults with urinary incontinence and its impact on the stigma-care needs network: latent profile and network analysis.BMC geriatrics · 2026Article
- A survivorship-oriented enhanced care model for patients undergoing radical prostatectomy.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Localized prostate cancer (PCa) remains the most common noncutaneous cancer in men, with numerous management options tailored to individual patient needs. This review examines the role of patient-reported outcomes (PROs) in guiding the management of localized PCa, focusing on the impact of various treatments on long-term quality of life. Standard therapies, including radical prostatectomy, radiotherapy, and active surveillance, are discussed alongside emerging focal therapies. Each treatment modality presents distinct risks, notably urinary incontinence, erectile dysfunction, bowel issues, and cancer recurrence. Understanding these adverse effects in terms of PROs is critical for patients and healthcare providers to engage in shared decision-making, enabling personalized treatment plans based on clinical outcomes and patient values. The incorporation of PROs into treatment selection emphasizes the significance of balancing oncologic control with functional outcomes, such as sexual, bowel, and urinary health. The importance of patient counseling is underscored, ensuring patients are fully informed about potential complications and long-term implications. This review advocates for personalized, evidence-based management strategies that align therapeutic decisions with individual patient preferences, optimizing both survival and quality of life. Enhanced communication between patients and clinicians, informed by PROs, is critical for minimizing decisional regret and maximizing satisfaction in the management of localized PCa.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.